Metadoxine

Quick links to important sections

Metadoxine

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metadoxine

Quick Facts

Property Description
Active Ingredient Metadoxine (a salt of Pyridoxine and L-Pyrrolidone Carboxylate)
Form Tablet, Solution for injection (IV/IM), Oral solution
Pharmacological Class Hepatoprotective agent, Alcohol-metabolism modulator
General Purpose Liver support and detoxification enhancement
Origin Synthetic compound (a pyridoxine derivative)

What Type of Medicine is Metadoxine?

Metadoxine is defined as a synthetic medicinal compound that functions primarily as a hepatoprotective agent and an alcohol-metabolism modulator. The molecule itself is a salt, chemically linking pyridoxine (a form of Vitamin B6) with L-pyrrolidone carboxylate (PCA). Metabolic regulatory actions have been observed in this compound, supporting its role as a specialized regulator and distinguishing it from simple vitamin supplements.

Composition and Available Pharmaceutical Forms

The core ingredient is Metadoxine, which combines both the vitamin derivative pyridoxine and the amino acid derivative pyrrolidone carboxylate in a single chemical entity. Metadoxine is manufactured for both oral and parenteral administration, typically available as tablets and as an aqueous solution for injection (intravenous or intramuscular). The availability of an injectable form is a differentiating factor, allowing for use in scenarios where rapid systemic action is required. The compound's composition is recognized for use in various liver-related contexts.

Metadoxine: Core Purpose and General Benefit

The general purpose of Metadoxine is to provide liver support and enhance the body's natural detoxification processes. As an alcohol-metabolism modulator, the compound is clinically recognized for assisting the system in accelerating the clearance of the toxic intermediate product acetaldehyde, which is crucial in reducing chemical stress. The primary benefit is supporting the hepatic system's ability to maintain its structural integrity and expedite the return to normal metabolic function.

Regulatory References

  1. clinically recognized

What side effects are possible with Metadoxine?

Possible Side Effects and Safety Information

The safety profile of Metadoxine, as outlined in official regulatory documents, is defined by categorized adverse reactions and specific usage constraints. Adverse effects are classified by their estimated frequency and the body system they affect.

Adverse Reaction Scope

Category Description
Frequency Classification Effects are typically classified in the Common or Rare categories. Common reactions include those affecting the nervous and gastrointestinal systems.
System-Organ Classes Involved Adverse reactions are documented within Gastrointestinal disorders (e.g., nausea, vomiting, abdominal pain, diarrhea) and Nervous System disorders (e.g., headache, dizziness, restlessness). Local reactions, such as pain at the injection site, are noted for the parenteral form.
Serious Adverse Reactions Rare but potentially serious events include severe allergic reactions or hypersensitivity responses, which may involve swelling, difficulty breathing, or tachycardia (fast heartbeat).

Regulatory Safety Constraints

The official label documents specific limitations and cautions for use.

  • Contraindication: Metadoxine is restricted for use in individuals with known hypersensitivity to the active substance or its components.
  • Population-Specific Caution: Use is generally not recommended during pregnancy and lactation due to limited safety data. Caution is advised for activities requiring alertness, such as driving or operating machinery, due to the potential for officially listed Nervous System effects.
  • Drug Interaction Note: A high-level safety note states that the pyridoxine component of Metadoxine may potentially diminish the therapeutic effectiveness of Levodopa.

These official classifications and constraints strictly define the medicine’s risk profile, ranging from frequently reported, non-serious systemic effects to rare but significant allergic responses and interactions.

Overdose and Emergency Response

Overdose and When to Seek Help

The official guidance regarding Metadoxine overdose is strictly focused on mandatory emergency response and universal management protocols. Regulatory documents generally do not detail a unique set of clinical manifestations, signs, or specific laboratory findings for an overdose of this particular compound. Therefore, the focus remains entirely on the required immediate actions defined by health authorities.


When Urgent Medical Help is Required

The ingestion of excessive amounts of Metadoxine constitutes an overdose situation. Official regulatory statements require that immediate medical attention be sought without delay for any suspected overdose. Contacting emergency services is the formally mandated action to ensure prompt initiation of medical evaluation and care by qualified professionals.


Official Overdose Management Principles

Principle Regulatory Statement
Documented Manifestations Not explicitly detailed in regulatory summaries.
Immediate Action Seek immediate medical attention.
Antidote Availability No specific antidote is known or formally listed.
Supportive Measures Management is restricted to symptomatic and supportive treatment.
Clinical Monitoring Hospital monitoring and continuous clinical observation are required following emergency action to manage potential outcomes.

The required care for Metadoxine overdose is defined as symptomatic and supportive, a classification necessitated by the absence of a specific reversal agent for the compound.

Therapeutic Uses of Metadoxine

What Metadoxine Treats: Main Uses and Benefits

The therapeutic utility of Metadoxine is generally used to provide hepatoprotective support and assists with symptom management in clinical contexts related to alcohol consumption, and may be part of symptomatic management across acute and chronic phases of alcohol-induced stress. The medicine is commonly applied in conditions characterized by systemic imbalance and organ-specific functional stress, including acute alcohol intoxication, alcoholic fatty liver disease (steatosis), and as adjunctive support in severe alcoholic hepatitis.

Supportive Symptom Management

This domain covers the medicine’s use during episodes of immediate, excessive alcohol intake marked by symptoms related to neurological or muscular activity, such as acute disorientation and loss of motor coordination. This medicine may assist with the management of these toxic symptoms, which contributes to easing the overall symptom load and supports an improved sense of stability and comfort. For chronic conditions, it may support the maintenance of liver function markers and may assist with managing or easing the progression of fat accumulation in the liver. This use is relevant when supportive symptom management is appropriate and may help patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Alcohol-Related Stress

Property Description
Primary Use Focus Liver support in alcohol toxicity (acute and chronic)
Symptom Management Symptoms of acute intoxication, elevated liver enzymes
Benefits Contributes to easing symptom burden, supports functional stability
Clinical Scenarios Emergency intervention, long-term disease management (steatosis)

Regulatory References

  1. NIH PubMed Central Review

Eligibility and Restrictions for Use

The eligibility profile for Metadoxine is structured by official regulatory documents, identifying specific populations who must not use the medicine and those who require conditional use.

Contraindications and Restrictions

Use is absolutely contraindicated in patients with a known hypersensitivity or allergy to Metadoxine or its components (pyridoxine or pidolic acid). Furthermore, the medicine must not be used in cases of severe liver impairment.

Age and Physiological Status

Age-related rules state that Metadoxine is not recommended for children under 13 years old because its safety and effectiveness have not been established in this pediatric group. The primary population for use is adults and adolescents aged 13 and older.

Restrictions also apply to special physiological states: Metadoxine is not recommended for use during pregnancy or breastfeeding. In these situations, use is conditional and permitted only if a medical professional determines that the potential benefits clearly outweigh the risks.

Condition-Specific Limitations

Special caution and possible dose adjustment are required for patients with pre-existing kidney disease (renal impairment). The eligibility status is thus strictly defined by allergic history, disease severity, and patient demographic/physiological status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Metadoxine describes a limited interaction profile centered on its chemical composition and primary metabolic function.

Feature Official Regulatory Statement
Medicinal product categories with documented interactions DOPA decarboxylase inhibitors, Antacids, Alcohol (Ethanol).
Specific interacting medicines (if explicitly listed) Levodopa, Aluminium-containing Antacids.
Mechanistic basis of interactions (only if stated in label) Pharmacodynamic antagonism (with Levodopa); Altered absorption kinetics (with Antacids); Metabolic Modulation (with Alcohol).

Official interaction statements:

  • Co-administration with Levodopa (L-DOPA), when used without a peripheral DOPA decarboxylase inhibitor, may result in a reduced therapeutic effect. This is a documented pharmacodynamic interaction related to the drug's pyridoxine component.
  • The co-administration of aluminium-containing antacids may lead to decreased oral absorption of Metadoxine, which could lower systemic exposure. This is noted in regulatory summaries regarding absorption kinetics.
  • Metadoxine is officially documented as an alcohol-metabolism modulator that increases the clearance rate and accelerates the elimination of ethanol from the blood.

The regulatory profile does not specify any clinically significant CYP enzyme metabolism, transporter-mediated effects, or mandatory timing separation rules for other medicinal products. The profile centers on a pharmacodynamic antagonism and a metabolic modulation consistent with the drug’s intended use.

Mechanism of Action

Dual-Action Modulation of Hepatic Enzyme and Antioxidant Systems

The mechanism centers on reinforcing the liver's capacity to manage metabolic processes through two synergistic actions: maintaining the activity of the key enzymes Alcohol Dehydrogenase (ADH) and Acetaldehyde Dehydrogenase (ALDH), which are responsible for supporting the rate of breakdown of ethanol and the metabolite acetaldehyde. Simultaneously, the drug supports the synthesis of the master antioxidant Glutathione (GSH), which directly neutralizes reactive oxygen species (ROS) and prevents the damaging process of lipid peroxidation. These combined actions result in a reduced exposure of hepatic tissues to toxic metabolites and contribute to the maintenance of hepatocyte membrane integrity.


Targeted Modulation of Neurotransmitter Systems

In the central nervous system (CNS), the drug exhibits a distinct neuromodulatory mechanism by acting as a selective antagonist at the Serotonin 5HT2B receptor and influencing the GABA Transporter (GAT-1). This dual modulation shifts the balance of CNS excitability toward an inhibitory state via increased GABA availability. This central action results in the modulation of neuropsychic signaling dynamics following metabolic perturbations.


Influence on Hepatic Lipid Metabolism Pathways

Metadoxine also engages in the regulation of pathways governing fat accumulation in the liver. Its mechanism involves inhibiting the phosphorylation of CREB (cAMP response element-binding protein), a transcription factor involved in lipid synthesis gene expression. This molecular sequence contributes to the attenuation of intracellular fat accumulation, resulting in a modulation of lipid homeostasis within hepatocytes.

Dosage and Administration Information

How to Use Metadoxine

Metadoxine administration follows distinct protocols dictated by the clinical scenario, utilizing either the oral route via tablets or the parenteral route via intravenous (IV) or intramuscular (IM) injection. The choice of route and dose is based on the therapeutic duration and the required speed of systemic action, reflecting established clinical procedures.


Official Administration Guidelines

Property Instruction
Administration Routes Administration is approved for the Oral, Intravenous (IV), and Intramuscular (IM) routes.
Dosing Schedule Chronic Oral Use: Standard regimens often detail a total daily dose of 1500 mg, typically divided and taken as 500 mg three times daily. Acute Parenteral Use: Single doses range from 300 mg to 900 mg.
Frequency Pattern Divided daily use (two to three times per day) for long-term courses; Single dose for acute parenteral intervention.
Timing in Relation to Meals The oral tablet form is advised to be administered after meals.
Special Handling The solid oral tablet form must be administered whole and is not to be broken, crushed, or chewed. Parenteral delivery requires preparation for intravenous infusion.
Course Duration Chronic Use: Treatment is often provided in courses lasting up to three months.

Connection to the Overall Use Protocol

Official instructions establish a dual-pathway procedural structure: a parenteral route for rapid, high-dose, short-term administration and an oral route for structured, long-term maintenance courses. These guidelines ensure correct administration by dictating specific intake conditions, such as the time relation to meals for the tablet and the necessary infusion technique for the solution, defining the standardized approach to proper use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Metadoxine

Evidence for Alcoholic Fatty Liver Disease (Steatosis)

The clinical evaluation of Metadoxine for alcoholic fatty liver disease, an early stage of liver damage, primarily relies on randomized, double-blind, placebo-controlled trials (RCTs). These studies were designed to explore how the compound relates to markers of liver function and the visible outcomes related to structural change.

Researchers monitored adults with chronic alcoholism and a confirmed diagnosis of fatty liver disease over short-term periods, typically lasting around three months. Trials reported that patterns of change in the measured liver enzyme levels were noted in the groups studied, with different observation periods described in the metadoxine groups compared to the placebo groups. Reported observations described a pattern of change in the measurement of fat accumulation in the liver in some study participants; findings describe patterns observed in the groups receiving the compound. What remains uncertain is the long-term impact, as primary research explored short-term symptom changes, meaning data are limited regarding how these observed measurements translate into outcomes over many months or years.

Evidence for Acute Alcohol Intoxication

Research was evaluated in acute settings, specifically exploring short-term symptom changes following excessive alcohol consumption. Studies were typically structured as short, controlled clinical trials that monitored temporary physiological imbalance over a limited number of hours.

Findings reported in these trials monitored the rate of alcohol elimination from the blood and recorded how clinical symptoms evolved in the observed populations, when compared to the group receiving standard treatment alone. Research provides insight into short-term changes observed over the acute observational period; there is limited information for long-term outcomes relevant to a single acute episode.

Evidence for Severe Alcoholic Hepatitis (Adjunctive Use)

Metadoxine was also evaluated as an adjunctive (added) agent alongside standard therapy for patients with severe alcoholic hepatitis (SAH), a critical condition involving high mortality. In some trials, patterns related to short-term survival were observed in groups receiving Metadoxine in combination with standard care compared to groups receiving monotherapy. The certainty of the evidence in this area remains low, as scientific reviews indicate that findings were mixed and the trials themselves are often smaller due to the high mortality and critical nature of SAH.

What is Still Uncertain About Metadoxine Research

Evidence quality varies across studies, with data for severe alcoholic hepatitis characterized as having low consistency. The overall evidence landscape has several gaps and limitations documented in scientific reviews, including the limited follow-up duration in primary trials, meaning long-term effects are not fully established. Research data also remains insufficient for certain groups, such as children, older adults, or women who are pregnant or breastfeeding.

Frequently Asked Questions (FAQ)

Common questions about Metadoxine (FAQ)

Q: Is Metadoxine the same as Pyritinol or other similar liver support supplements?

A: Metadoxine is classified as a synthetic medicinal compound that acts as a hepatoprotective agent and an alcohol-metabolism modulator. Official documentation indicates it is a salt chemically linking pyridoxine (Vitamin B6) and L-pyrrolidone carboxylate. This composition and specific regulatory classification help distinguish it from simple vitamin supplements. Official documents do not include specific comparisons to products like Pyritinol.

Q: Does Metadoxine really help with alcohol detox or hangovers?

A: Studies and official information indicate that Metadoxine is documented to accelerate the elimination of ethanol and acetaldehyde, which supports the body's metabolic processes related to alcohol clearance. This function is the basis for its use in contexts such as acute alcohol intoxication.

Q: Can Metadoxine improve concentration or brain function?

A: Metadoxine's mechanism involves a central action that modulates neurotransmitter systems, such as GABA and Serotonin, in the brain. However, official labels also list nervous system side effects like dizziness and restlessness, which means that potential nervous system side effects should be monitored.

Q: Is it normal to feel a bit nauseous when starting Metadoxine?

A: Yes, regulatory documents list nausea as a common adverse reaction associated with Metadoxine use. Other common gastrointestinal side effects listed in the product information include vomiting, abdominal pain, and diarrhea.

Q: Does Metadoxine interact with common over-the-counter painkillers?

A: Official documentation does not specify an interaction with common over-the-counter painkillers, such as nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen. Documented interactions in official regulatory summaries are limited to specific substances such as Levodopa, aluminium-containing antacids, and alcohol.

Q: Can Metadoxine be taken long-term for liver maintenance?

A: Official guidelines indicate that treatment for chronic oral use is often provided in courses lasting up to three months in clinical trials. Scientific reviews have noted that safety data is limited and any use beyond the typical course duration requires professional guidance.

Q: Is Metadoxine safe for older adults?

A: The primary population for Metadoxine use is defined as adults and adolescents aged 13 and older. However, regulatory summaries indicate that safety data remains insufficient for certain groups, including older adults, which suggests that any use in this population requires careful professional evaluation.

Q: Are there any known interactions between Metadoxine and vitamins/minerals?

A: Official interaction documentation focuses on the prescription drug Levodopa, aluminium-containing antacids, and alcohol. The regulatory profile does not specify or mandate warnings regarding clinically significant interactions with general vitamins or minerals.

Q: Are headaches a common side effect of Metadoxine?

A: Yes, official safety information lists headaches as a common adverse reaction that can affect the nervous system. Other common effects include dizziness and restlessness.

Q: Does food change how Metadoxine is absorbed?

A: Official administration guidelines state the oral tablet form is advised to be administered after meals. Additionally, regulatory information notes that co-administering aluminium-containing antacids may lead to decreased oral absorption of Metadoxine.

Q: Is Metadoxine safe for people with high blood pressure?

A: Official product information does not specifically list high blood pressure (hypertension) as a contraindication or caution for use. However, the official label does list tachycardia (fast heartbeat) as a rare adverse event, which should be noted.

Q: Can Metadoxine be used by people who are trying to reduce alcohol consumption?

A: As an alcohol-metabolism modulator, Metadoxine is officially documented to accelerate the elimination of ethanol. Its clinical use is recognized for acute alcohol intoxication and in supporting liver function in the context of chronic alcohol use.

Q: Is it true that Metadoxine can help with symptoms of alcoholic withdrawal?

A: The drug is used in the context of acute alcohol intoxication and its mechanism involves modulating CNS excitability via the GABA system. However, regulatory summaries do not explicitly list 'withdrawal syndrome' as a defined indication for use.

Q: Can Metadoxine cause any allergic reactions?

A: Yes, official safety information states that a known hypersensitivity or allergy to Metadoxine is an absolute contraindication for use. Rare, but potentially serious, events include severe allergic reactions or hypersensitivity responses.

Q: Why is Metadoxine sometimes called pyridoxine pyrrolidone carboxylate?

A: This alternative name is based on the drug’s chemical structure. Metadoxine is a salt that chemically links two components: pyridoxine (a form of Vitamin B6) and L-pyrrolidone carboxylate (PCA).

Q: Does Metadoxine have any impact on mood or anxiety?

A: Metadoxine's mechanism involves neurotransmitter modulation and influencing the GABA system in the central nervous system. Officially, the label lists restlessness as a possible nervous system side effect.

Q: Are pregnant or breastfeeding people allowed to use Metadoxine?

A: Regulatory information indicates that Metadoxine is not recommended for use during pregnancy or breastfeeding due to limited safety data. Use is conditional, permitted only if a medical professional determines that the potential benefits clearly outweigh the risks.

Q: Does Metadoxine help reduce fat buildup in the liver?

A: The mechanism of action involves regulating hepatic lipid metabolism by inhibiting a factor (CREB) that influences fat synthesis gene expression. This action contributes to the attenuation of intracellular fat accumulation in liver cells.

Q: Do you need to adjust your diet while taking Metadoxine?

A: Official guidelines advise that the oral form of Metadoxine should be taken after meals. Additionally, alcohol consumption should be avoided while taking this medication.

Q: Do interactions with Metadoxine usually happen with prescription drugs only?

A: No, official documentation lists interactions with the prescription drug Levodopa, but also includes the non-prescription products aluminium-containing antacids and alcohol (ethanol). The interaction profile is not limited to prescription medicines.

Q: Can Metadoxine affect sleep or cause insomnia?

A: The official label lists restlessness as a common adverse reaction affecting the nervous system. Due to this potential effect, patients are cautioned about activities requiring alertness.

Q: Does Metadoxine require special storage conditions?

A: Official requirements state the medication must be stored in a cool, dry place, protected from direct sunlight, excessive heat, and moisture. Storage is typically required at room temperature, and it must be kept in the original container.

Q: Are there any known cases of Metadoxine causing kidney problems?

A: Regulatory documents advise that special caution and possible dose adjustment are required for patients who have pre-existing kidney disease (renal impairment). The official label does not contain a statement documenting Metadoxine as a cause of kidney failure.

How should Metadoxine be stored and disposed of?

How to Store and Dispose of Metadoxine?

Storage Component Official Requirement
Environmental Control Store in a cool, dry place, protected from direct sunlight, excessive heat, and moisture.
Temperature Storage is typically required at room temperature, often below 25 C or 30 C.
Packaging Rules Must be kept in the original container until use to maintain product integrity.
Child Safety The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Official disposal procedures prioritize the use of an authorized drug take-back program or specialized collection site for unused or expired Metadoxine. As the medicine is not on the U.S. FDA's list of flushable medications, it must not be disposed of by pouring it down a drain or flushing it down a toilet. All personal information on the packaging must be removed before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Metadoxine found in:

A-Z Index: